检索结果-南通市图书馆

Use of intra-arterial chemotherapy for retinoblastoma:results of a survey

International Journal of Ophthalmology(English edition) 2014年第4期7卷 726-730页

作者： Nathalia Grigorovski evandro lucena Clarissa Mattosinho Andreu Parareda Sima Ferman Jaume Catalá Guillermo Chantada Department of Pediatric Oncology Instituto Nacional de Cncer Ophthalmic Oncology Service Instituto Nacional de Cncer Oncology Service Hospital Sant Joan de Deu Esplugues de Llobregat Ophthalmology Service Hospital Sant Joan de DeuEsplugues de Llobregat

·AIM: To obtain baseline knowledge about the current use of intra-arterial chemotherapy(SSOAIC) in centers worldwide.·METHODS: A survey including questions about the use of SSOAIC was emailed to retinoblastoma experts.·RESULTS:Seventy-nine(response rate 69.9%) doctors from 63 centers in 35 countries responded. Thirty-one centers from 19 countries use SSOAIC. Twelve performed more than 50 procedures. Melphalan is the most commonly used drug but 15 centers use more than one drug. First line therapy for advanced unilateral disease is the most common use of SSOAIC(74.2%). Centers with larger experience(>50 applications) were less likely using melphalan alone(P =0.06) and significantly more likely using SSOAIC in more situations such as second line in preference to radiotherapy P =0.05. Nineteen(61.2%)stated that SSOAIC improved their results and 21(77.8%)reported less toxicity compared to other *** centers reported that SSOAIC did not improve their results. There were regional variations in the use of SSOAIC which is used more frequently as secondary treatment in Europe compared to the USA and *** centers identified cost is the major limiting factor for SSOAIC.· CONCLUSION: SSOAIC is used in an increasing number of centers worldwide with regional *** with more experience in SSOAIC use it in more situations including other drugs than melphalan. The majority of the centers using this technique reportedimproved results and few complications.

关键词： retinoblastoma intra-arterial chemotherapy survey

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

An international survey of classification and treatment choices for group D retinoblastoma

引用

International Journal of Ophthalmology(English edition) 2017年第6期10卷 961-967页

作者： Christina Scelfo Jasmine H Francis Vikas Khetan Thomas Jenkins Brian Marr David H Abramson Carol L Shields Jacob Pe’er Francis Munier Jesse Berry J.William Harbour Andrey Yarovoy evandro lucena Timothy G Murray Pooja Bhagia Evelyn Paysse Samuray Tuncer Guillermo L Chantada Annette C Moll Tatiana Ushakova David A Plager Islamov Ziyovuddin Carlos A Leal Miguel A Materin Xun-Da Ji Jose W Cursino Rodrigo Polania Hayyam Kiratli Charlotta All-Ericsson Rejin Kebudi Santosh G Honavar Vicktoria Vishnevskia-Dai Sidnel Epelman Anthony B Daniels Jeanie D Ling Fousseyni Traore Marco A Ramirez-Ortiz Ophthalmic Oncology Service Department of Surgery Memorial Sloan Kettering Cancer Center New York 10065 USA Department of Ophthalmology Weill-Cornell Medical Center New York 10065 USA Department of Vitreoretinal and Ocular Oncology Sankara Nathralaya Chennai 600066 India Ocular Ontology Service Wills Eye Hospital Thomas Jefferson University Pennsylvania 19107 USA Hadassah - Hebrew University Medical Center Jerusalem 91120 Israel jules-Gonin Eye Hospital Lausanne 1004 Switzerland USC Roski Eye Institute Children＇s Hospital of Los Angeles California 90033 USA Ocular Oncology Service Bascom Palmer Eye Institute University of Miami Miller School of Medicine Florida 33136 USA Ocular Oncology Department S.N. Fyodorov Eye Microsurgery Federal State Institution Moscow 127486 Russia Department of Ocular Oncology Instituto Nacional de Cancer Rio de Janeiro 1122 Brazil Murray Ocular Oncology and Retina Miami Children＇s Hospital Florida 33143 USA St. Joseph＇s Children＇s Hospital New Jersey 07504 USA Department of Ophthalmology Baylor College of Medicine Texas 77030 USA Department of Ophthalmology Ocular Oncology Istanbul Medical Faculty Istanbul University Istanbul 34452 Turkey Oncology Department Hospital JP Garrahan Buenos Aires 1245 Argentina Department of Ophthalmology VU University Medical Center Amsterdam 1081 the Netherlands Department of Head and Neck Tumors Science Research Institute of Pediatric Oncology and Hematology N.N. Blokhin Russian Cancer Research Center Moscow 115478 Russia Pediatric Ophthalmology and Adult Strabismus Riley Hospital for Children Indiana University Medical Center Indiana 46202 USA National Oncology Center of Uzbekistan Tashkent 110508 Uzbekistan nstituto Nacional de Pediatria Coyoacan 04530 Mexico Department of Ophthalmology and Visual Science Smilow Cancer Hospital at Yale New Haven CT 06520 USA Xin Hua Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200092 China Department of Ophthalmology Santa Casa Mi

AIM： To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. METHODS： An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. RESULTS： The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Children＇s Hospital of Los Angeles （CHLA） version, 33% used the Children＇s Oncology Group （COG） version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were： Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were： Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center （P〈0.0001）. CONCLUSION： Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic r

关键词： retinoblastoma oncology retina enucleation chemotherapy intra-arterial chemotherapy ophthalmic arterychemosurgery cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：